Future Science OA最新文献_第3页

Colonic strictures in Crohn's disease: a non-surgical survival. 结肠狭窄在克罗恩病：非手术生存。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-25 DOI: 10.1080/20565623.2025.2455911

Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker

{"title":"Colonic strictures in Crohn's disease: a non-surgical survival.","authors":"Sarra Laabidi, Hamed Aboubecrine, Salma Souissi, Donia Gouiaa, Asma Labidi, Nadia Ben Mustapha, Anis Haddad, Amine Sebai, Meriem Serghini, Monia Fekih, Hanene Jaziri, Jalel Boubaker","doi":"10.1080/20565623.2025.2455911","DOIUrl":"10.1080/20565623.2025.2455911","url":null,"abstract":"Background: Colonic stenosis in Crohn's disease (CD) is uncommon, and data on surgery-free survival are limited. This study aimed to determine surgery-free survival rates and identify associated factors.Patients and methods: A retrospective study was conducted from 2003 to 2022, including patients with CD complicated by colonic stenosis. Patients with uncertain diagnoses or follow-up periods of less than six months were excluded.Results: Fifty-six patients were included (median age 44 years [range 14-65], male-to-female ratio = 0.93). Surgery-free survival rates were 58.9% at 6 months, 43.7% at 2 years, and 31.7% at 5 years, with an average surgery-free survival of 46.7 months. Univariate analysis showed that joint manifestations (p = 0.01), corticosteroids (p = 0.02), anti-TNF alpha (p = 0.02), salicylates (p = 0.02), and azathioprine (p = 0.01) increased surgery-free survival. Complications such as collections or internal fistulas (p = 0.03), parietal ulceration on imaging (p = 0.01), and acute intestinal obstruction (p = 0.01) were associated with reduced surgery-free survival. In multivariate analysis, biologic therapy was the only independent protective factor against surgery (p = 0.001, OR = 0.19).Conclusion: The early introduction of biologic therapy is crucial for increasing surgery-free survival in patients with colonic stenosis in CD, given the limited effectiveness of conventional treatments.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2455911"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA: in vitro and in silico studies. 通过MRSA抑制克林霉素耐药性的植物治疗方法：体外和计算机研究。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-02 DOI: 10.1080/20565623.2025.2458438

Amal Mayyas, Ali Al-Samydai, Nehaya Al-Karablieh, Waleed A Zalloum, Deniz Al-Tawalbeh, Farah Al-Mamoori, Rula A Amr, Hamdi Al Nsairat, Simone Carradori, Lidia Kamal Al-Halaseh, Talal Aburjai

{"title":"A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA: in vitro and in silico studies.","authors":"Amal Mayyas, Ali Al-Samydai, Nehaya Al-Karablieh, Waleed A Zalloum, Deniz Al-Tawalbeh, Farah Al-Mamoori, Rula A Amr, Hamdi Al Nsairat, Simone Carradori, Lidia Kamal Al-Halaseh, Talal Aburjai","doi":"10.1080/20565623.2025.2458438","DOIUrl":"10.1080/20565623.2025.2458438","url":null,"abstract":"Aims: This study investigates the potential effects of essential oils (EOs) in enhancing the efficacy of clindamycin against Methicillin-resistant Staphylococcus aureus (MRSA) using in vitro and computer simulations. The research seeks to identify essential oils that exhibit synergistic activity with clindamycin and determine their potential key active components.Materials and methods: Essential oils commonly used in traditional medicine were tested for their antimicrobial activity against MRSA. The minimum inhibitory concentration (MIC) was determined using in vitro microdilution assays. A synergistic test with clindamycin was performed, and molecular docking studies evaluated the interaction between a key compound (trans-cinnamaldehyde) and MRSA protein.Results: EOs from Cinnamomum verum, Rosmarinus officinalis, Salvia officinalis, and Thymus vulgaris demonstrated significant inhibitory and synergistic activities against MRSA, standard strain, and human clinical isolates. Gas Chromatography/Mass Spectroscopy identified trans-cinnamaldehyde, eucalyptol, and thymol as prominent antibacterial compounds. Molecular docking studies confirmed trans-cinnamaldehyde's strong binding to MRSA's AgrA protein, elucidating its enhanced efficacy.Conclusion: The study underscores the potential of plant-based therapies to augment the effectiveness of conventional antibiotics like clindamycin in combating MRSA and addressing antibiotic resistance by integrating traditional plant remedies with modern medical approaches.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2458438"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of peripheral blood microRNAs in the pathogenesis and treatment response of age-related macular degeneration. 外周血microrna在老年性黄斑变性发病机制和治疗反应中的作用。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-04-04 DOI: 10.1080/20565623.2025.2482499

Meng Kong, Jingwen Li, Nianting Tong

引用次数: 0

Prevalence and risk factors of H. pylori infection among outpatient in Karaganda city (Kazakhstan). 哈萨克斯坦卡拉干达市门诊患者幽门螺杆菌感染流行及危险因素分析

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-10 DOI: 10.1080/20565623.2025.2461429

Aizhan Seisenbekova, Yelena Laryushina, Yekaterina Yukhnevich, Alyona Lavrinenko, Alexey Shkreba

引用次数: 0

User-friendliness of the pain assessment in impaired cognition (PAIC15) in persons with aphasia: a pilot study. 失语症患者认知障碍疼痛评估的用户友好性（PAIC15）：一项试点研究。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-01-27 DOI: 10.1080/20565623.2025.2456440

Neeltje J de Vries, Hanneke J A Smaling, Jenny T van der Steen, Wilco P Achterberg

引用次数: 0

Atypical acquired hemophilia linked with primary biliary cholangitis: a unique case presentation. 非典型获得性血友病与原发性胆道胆管炎：一个独特的病例介绍。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-04-07 DOI: 10.1080/20565623.2025.2489329

Fatma Megdiche, Nour Siala, Faten Kallel, Imen Krichen, Hend Hachicha, Imen Frikha, Maha Charfi, Naourez Kallel, Moez Medhaffar, Hatem Masmoudi, Moez Elloumi, Choumous Kallel

引用次数: 0

Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model. 评价胞苷、尿苷和加巴喷丁联合使用对神经性模型疼痛调节和p-CREB表达的影响。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-31 DOI: 10.1080/20565623.2025.2483137

Esam Y Qnais, Muna Barakat, Rabaa Y Athamneh, Mohammad A A Al-Najjar, Lujain F Alzaghari, Dinesh Kumar Chellappan, Abdelrahim Alqudah

{"title":"Evaluating cytidine, uridine, and gabapentin combinations for pain modulation and p-CREB expression in neuropathic model.","authors":"Esam Y Qnais, Muna Barakat, Rabaa Y Athamneh, Mohammad A A Al-Najjar, Lujain F Alzaghari, Dinesh Kumar Chellappan, Abdelrahim Alqudah","doi":"10.1080/20565623.2025.2483137","DOIUrl":"10.1080/20565623.2025.2483137","url":null,"abstract":"Aims: To evaluate the analgesic and neuroprotective effects of cytidine, uridine, and gabapentin-administered alone and in combination-in models of diabetic neuropathy and formalin-induced acute and inflammatory pain.Materials & methods: Oral doses of cytidine, uridine, and gabapentin (100 mg/kg each) were administered to rats with streptozotocin-induced diabetic neuropathy and in a formalin test model. Behavioral responses were recorded at 30, 60, and 120 minutes following treatment after five weeks of diabetes induction. Spinal cord p-CREB expression was measured to assess molecular changes, and pretreatments with naloxone, yohimbine, and methysergide were employed to explore opioid, adrenergic, and serotonergic contributions.Results: All treatments significantly reduced formalin-induced pain in both acute and inflammatory phases (p < 0.05; p < 0.001) and increased mechanical pain thresholds in the diabetic neuropathy model at all-time points (p < 0.05). Combination therapy proved more effective than gabapentin alone (p < 0.05) and was associated with decreased spinal p-CREB levels, indicating altered anti-nociceptive signaling.Conclusions: The combined use of cytidine, uridine, and gabapentin enhances analgesia and neuroprotection compared to monotherapy, supporting its potential as a novel, analgesic-free treatment strategy for diabetic neuropathy.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2483137"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Computer vision syndrome: a comprehensive literature review. 计算机视觉综合征：综合文献综述。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-08 DOI: 10.1080/20565623.2025.2476923

Fares Kahal, Ahmad Al Darra, André Torbey

{"title":"Computer vision syndrome: a comprehensive literature review.","authors":"Fares Kahal, Ahmad Al Darra, André Torbey","doi":"10.1080/20565623.2025.2476923","DOIUrl":"10.1080/20565623.2025.2476923","url":null,"abstract":"Computer Vision Syndrome is a growing health concern in the digital age, with a reported prevalence of 69.0%. It is caused by screen-related, environmental, ergonomic, and physiological factors, affecting diverse demographics. The COVID-19 pandemic significantly amplified CVS due to increased screen time for remote work, online learning, and social media use, with studies reporting symptoms in up to 74% of individuals. Unique visual challenges from digital screens, including reduced clarity and glare, exacerbate symptoms like dry eyes and discomfort, especially in those with uncorrected vision. Understanding CVS is crucial for mitigating its impact through effective prevention and management strategies. This study explores the causes, diagnosis, management, and prevention strategies of CVS by synthesizing recent findings from optometry, occupational health, digital health, and ergonomics. It also highlights emerging trends such as AI, wearables, and augmented reality while providing practical management strategies. A narrative review of literature from 2014 to 2024 was conducted, focusing on PubMed-indexed, peer-reviewed articles, including meta-analyses and systematic reviews, with priority given to recent, highly cited studies.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2476923"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management. 基于聚合物纳米颗粒的靶向递送药物和生物活性化合物用于关节炎管理。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-20 DOI: 10.1080/20565623.2025.2467591

Tanu Dixit, Anuradha Vaidya, Selvan Ravindran

{"title":"Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management.","authors":"Tanu Dixit, Anuradha Vaidya, Selvan Ravindran","doi":"10.1080/20565623.2025.2467591","DOIUrl":"10.1080/20565623.2025.2467591","url":null,"abstract":"This review explores the potential of polymeric nanoparticles (PNPs) as targeted drug delivery systems for arthritic treatment, overcoming the limitations of the present therapy. A thorough literature search was conducted on the databases PubMed, Scopus, and Web of Science to find published articles on the use of polymeric nanoparticles in the treatment of arthritis. This includes synthesis methods, mechanisms in drug delivery, and applications of PNPs. Polymeric nanoparticles showed excellent promise in the management of arthritis through enhanced stability of drugs, controlled and sustained drug release, and reduced systemic side effects. Some of the highlighted biocompatible and targeting capabilities of natural and synthetic polymers include chitosan, hyaluronic acid, and PLGA. Bioactive compounds such as curcumin and resveratrol delivered by PNPs enhanced therapeutic efficacy in preclinical arthritis models. Despite their promise, challenges such as rapid clearance and manufacturing scalability remain critical barriers. Polymeric nanoparticles offer a transformative approach to arthritis management by enabling targeted, sustained, and safe drug delivery. Translation into clinical applications would thus require developments in nanoparticle design, personalized medicine, and scalable production techniques.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2467591"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell therapies: patient access and affordability solutions. CAR-T细胞疗法：患者可及性和可负担性解决方案。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-29 DOI: 10.1080/20565623.2025.2483613

Elisabete Gonçalves

{"title":"CAR-T cell therapies: patient access and affordability solutions.","authors":"Elisabete Gonçalves","doi":"10.1080/20565623.2025.2483613","DOIUrl":"10.1080/20565623.2025.2483613","url":null,"abstract":"Chimeric Antigen Receptor (CAR)-T cell therapies, as potentially curative treatments, are a group of immunotherapy agents that are changing the paradigm for the treatment of hematologic malignancies. Ongoing research on CAR-T cell therapy is expected to expand the currently approved indications, which, given the high prices of these innovative therapeutic solutions, will increase the pressure on the sustainability of health systems, enhancing the need to establish adjusted financial solutions and promote the implementation of post-marketing monitoring procedures. This study examines the specific challenges in the development of robust clinical evidence to support the value measurement and cost-effectiveness assessment of CAR-T cell therapies and in the selection of adequate financing solutions. Managed Entry Agreements, which create mechanisms in which the risk associated with the uncertainty in long-term outcomes of these therapies is shared between the manufacturer and the payer, have emerged as preferred solutions in several European Union countries. The access barriers to CAR-T cell therapies are described, and recommendations on potential solutions to address affordability concerns using a framework of a life cycle approach to value assessment involving different stakeholders and adapted financing tools are proposed.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2483613"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0